Peter Thiel Quotes

Financial risk is always associated with drug discovery. But the benefit that a blockbuster drug can bring to the business can be phenomenal if you can take that risk.

Fundamental discoveries can and should be made in industry or academies, but to carry that knowledge forward and to develop a new drug to the market has to depend on the resources of industry.

Aspen's investment in TesoRx will assist in the work being undertaken to bring this product to market and in investing behind TesoRx's pipeline and technology that has the potential to be used for a wide range of different applications.

Getting a traditional pharmaceutical to the market can cost a billion dollars or more. Newer, more tailored and targeted drugs called biologics are even more complex and expensive. Simple economics dictates that companies and venture funds will invest more in products that can generate a sufficient return.

Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business.

If you go to the FDA with a drug that's only meant to treat 50 people, and it's a 95 percent cure rate, you'll get your drug approved.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

I used to be a health-care investor a long time ago in the public markets. One thing I learned that we tried to apply here is that investing in small molecules, trying to invest in the next treatment, there's an element of gambling to that.

I've heard drug experts say they believe if penicillin were discovered today, the FDA wouldn't license it.

In 15 years, we've raised $225 million, sequenced the myeloma genome, and opened 45 trials of 23 drugs - six approved by the FDA - which have doubled the life span of multiple myeloma patients. I've taken both Velcade and Revlimid, which we helped develop.

Over the years, HIV/AIDS activists and their allies have been pioneers in creating new frontiers in the medical establishment. Through their efforts, the FDA drug approval procedures were reformed so promising new therapies could reach desperate patients quicker.

When a company is fairly certain of a profit margin that is substantial, it can assume responsibility for the clinical trials to develop a blockbuster drug.

And there are lots of drug companies that are working on cure or medicine.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

We have 28,000 drug patents held by American universities that are not being developed.

There's no way we can invent enough stuff for a company of Merck's size.

To ensure that America remains the leader in medical innovation, we must reduce the costs of developing life-saving drugs and ensure that there are appropriate economic incentives in place to produce them.

It seems paradoxical that, as medical scientists make huge advances in discovering the mechanisms of common diseases, fewer and fewer innovative drugs are reaching the market.

There is no doubt that the Mindset failure is a major setback for Axovant, but it is not the end of the road.

It’s our tax dollars that fund the initial research for these molecules that get transferred to corporations. We have an investment here… We end up paying for our drugs twice. We pay for the initial development through our tax dollars. And then when it goes on the market we pay their inflated prices.

I don't program, so I don't belong in Silicon Valley. If I did belong in Silicon Valley, I'd be there creating a revolutionary compression algorithm for billions of dollars.

For decades, technology entrepreneurship has been revered, and people like Steve Jobs and Elon Musk were heroes.

Inventors often don't know how to pitch their ideas. So many people in Silicon Valley want to hear you say 'disruptive,' and tote a 'platform.' They repeat buzzwords over and over, and I think it intimidates a real inventor.

I fell in love with the science at Merck.

A vigorous and profitable drug industry is not a problem to be solved but a goal to be encouraged.